Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
AVITA Medical reports developments in therapeutic acute wound care, led by the RECELL platform for Spray-On Skin used in burn and trauma wounds. Company news commonly covers FDA-cleared wound-care indications, RECELL GO automation, international regulatory clearances, and the U.S. commercial portfolio that includes Cohealyx, a collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix.
Updates also include clinical data presentations, BARDA emergency-preparedness agreements, quarterly financial results, investor-conference participation, and board or executive governance changes. The recurring news themes connect AVITA Medical's product platform with acute burn care, trauma wound treatment, commercialization, reimbursement, and capital resources.
AVITA Medical (NASDAQ: RCEL) is hosting its virtual Acute Wound Care Showcase 2025 on May 13, 2025, at 11:00 a.m. Pacific Time. The event will feature presentations from leading burn and trauma clinicians using AVITA's technologies, alongside patient testimonials about their treatment experiences with the company's solutions.
CEO Jim Corbett and SVP of Scientific and Medical Affairs Dr. Katie Bush will present AVITA's integrated approach to acute wound care, highlighting key technologies including RECELL®, Cohealyx™, and PermeaDerm®. The showcase will include a live Q&A session, with registration available through the company's website. A replay will be accessible from May 14 on AVITA Medical's Investor Relations site.
AVITA Medical (NASDAQ: RCEL) has announced its inaugural Acute Wound Care Showcase 2025, scheduled for May 13, 2025, at 11:00 a.m. Pacific Time via webcast. The event will feature presentations from CEO Jim Corbett and Dr. Katie Bush, Senior Vice President of Scientific and Medical Affairs.
The showcase will highlight AVITA Medical's comprehensive approach to acute wound care, featuring their product portfolio including RECELL®, Cohealyx™, and PermeaDerm®. Attendees will gain insights through physician testimonials and, for the first time, hear directly from patients whose lives have been transformed by these technologies.
The event will demonstrate the clinical and economic benefits of AVITA's technologies and conclude with a live Q&A session. Interested parties can register through the Events & Presentations section of AVITA Medical's Investor Relations website, with a replay available the following day.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, after U.S. market close. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time (May 9, 2025, 6:30 a.m. Australian Eastern Standard Time) to discuss financial performance and recent business highlights.
Investors can access the live webcast through the Events & Presentations section on AVITA Medical's website at ir.avitamedical.com. For telephone participation, advance registration is required to receive dial-in details and a personal PIN.
AVITA Medical (NASDAQ: RCEL) announced the presentation of 16 abstracts at the American Burn Association (ABA) 2025 Annual Meeting in Phoenix, showcasing data across their wound care portfolio including RECELL®, Cohealyx™, and PermeaDerm®.
Key findings include:
- Pre-clinical study on Cohealyx showing support for wound bed vascularization within 7 days
- Largest real-world analysis of over 6,000 RECELL-treated patients demonstrating increasing adoption and consistent clinical utility
- New clinical data on PermeaDerm as an effective temporary wound coverage solution
- Randomized multicenter trial results showing PermeaDerm reduces dressing change frequency and supports early wound healing
The company aims to address the needs of over 450,000 Americans requiring medical treatment for burn injuries annually, focusing on earlier wound closure and reduced procedural complexity.
AVITA Medical (NASDAQ: RCEL) has launched Cohealyx™, a collagen-based dermal matrix co-developed with Regenity Biosciences, expanding its therapeutic wound care portfolio. The product is designed to facilitate cellular migration and revascularization for wound bed preparation, with integrated wound bed formation observed as early as 7 days in initial testing.
Cohealyx complements AVITA's existing products - the RECELL® System (FDA-approved for thermal burns and full-thickness skin defects) and PermeaDerm® (a temporary biosynthetic dressing). This integrated approach supports the two-stage standard of care for full-thickness wounds.
The company is currently conducting the Cohealyx I trial, a post-market study evaluating clinical outcomes and wound bed preparation effectiveness. Pre-clinical studies showed faster graft-ready results compared to leading competitors, potentially leading to shorter hospital stays.
AVITA Medical (NASDAQ: RCEL) has announced new strategic agreements with Stedical Scientific for PermeaDerm® Biosynthetic Wound Matrix. The company will now manufacture PermeaDerm at its Ventura, California facility under a new Contract Manufacturing Agreement effective March 17, 2025.
Key changes include:
- AVITA Medical will now retain 60% of average sales price (up from 50%) after deducting manufacturing costs
- Stedical will receive 40% of sales price (down from 50%)
- The agreement includes new performance-based milestones and extended contract terms
PermeaDerm, an FDA-cleared biosynthetic matrix for wound healing, is reimbursable across U.S. inpatient and outpatient settings. It can be used with AVITA's RECELL® devices and Spray-On Skin™ Cells for various wound types.
AVITA Medical (NASDAQ: RCEL), a therapeutic acute wound care company, has announced its upcoming participation in TD Cowen's 45th Annual Health Care Conference. Jim Corbett, the company's Chief Executive Officer, is scheduled to present on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time.
The presentation will be accessible through a live audio webcast on the Events & Presentations section of AVITA Medical's investor relations website. Interested parties can access the webcast at https://ir.avitamedical.com, and a replay will be made available after the event concludes.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a therapeutic acute wound care company, has announced an upcoming investor webinar briefing scheduled for February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).
The presentation will be led by CEO Jim Corbett and CFO David O'Toole, focusing on the company's financial and business results from their recent fourth quarter and full-year 2024 earnings webcast. The event will include a Q&A session, with participants able to submit questions through the registration page.
Interested shareholders and prospective investors can register for the webinar via a provided Zoom link. A replay of the presentation will be made available on the AVITA Medical investor relations website.
AVITA Medical (NASDAQ: RCEL) reported its Q4 and full-year 2024 financial results. Q4 commercial revenue reached $18.4 million, up 30% year-over-year, with an 87.6% gross profit margin. Full-year 2024 revenue was $64.0 million, increasing 29% from 2023, with an 85.8% gross margin.
Key developments include FDA clearance for Cohealyx™ and RECELL GO® mini in December 2024. The company provided 2025 revenue guidance of $100-106 million, projecting 55-65% growth. AVITA expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025.
Q4 net loss was $11.6 million ($0.44 per share), compared to $7.1 million loss in Q4 2023. Full-year 2024 net loss increased to $61.8 million ($2.39 per share). The company ended 2024 with $35.9 million in cash and equivalents.